Visit
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
EHA 2021
Find out more about novel developments in R/R #Hodgkin lymphoma, including the promise of checkpoint inhibitors, bispecifics and CAR-T cells, in our exclusive interview with Graham Collins (@graham74GC):
👉http://ow.ly/9aXO50LM8BP👈
#LymSM #ImmunoOnc #HemOnc #ISHL12
#ESHCML2022 | Camille Kockerols (@asznl) comments on the efficacy and tolerability of asciminib in patients with CML who are intolerant or resistant to TKIs:
🎥: http://ow.ly/1Nxh50LM89Q
@ESHaematology #LeuSM #CMLsm #HemOnc
Let’s learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and dedicated time, efforts, ressources and energy to try to advance the field. A negative tweet is easy to write, but spending 5y to run a trial is another story https://twitter.com/Mohty_EBMT/status/1595293396297449472
We shouldn’t celebrate failure of a drug, celebrate learning instead because there’s always a path forward “I’ve missed more than 9000 shots in my career. I’ve lost almost 300 games…I’ve failed over and over and over again in my life. And that is why I succeed” – M Jordan #ASH22
Saad Kenderian (@kenderian_ss) of @MayoClinic discusses the current challenges and opportunities regarding CAR-T cell therapy and the tumor microenvironment at #SOHO22:
🎥: http://ow.ly/Kf0Q50LM7L3
#HemOnc #ImmunoOnc #CARTcell
EHA 2021
The 26th Congress of the European Hematology Association (EHA) 2021, 9-17 June, will see leading experts from around the globe gather virtually for a fantastic demonstration of the most ground-breaking research in the field of hematology.
Exciting data on promising biomarkers, CAR T-cell and NK-cell therapy, transplant research, novel drugs and more will be showcased across the spectrum of hematological diseases, including CLL, AML, multiple myeloma, lymphomas, CML, ALL, sickle cell disease, thalessemia, and beyond.
Find out more about novel developments in R/R #Hodgkin lymphoma, including the promise of checkpoint inhibitors, bispecifics and CAR-T cells, in our exclusive interview with Graham Collins (@graham74GC):
👉http://ow.ly/9aXO50LM8BP👈
#LymSM #ImmunoOnc #HemOnc #ISHL12
#ESHCML2022 | Camille Kockerols (@asznl) comments on the efficacy and tolerability of asciminib in patients with CML who are intolerant or resistant to TKIs:
🎥: http://ow.ly/1Nxh50LM89Q
@ESHaematology #LeuSM #CMLsm #HemOnc
Let’s learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and dedicated time, efforts, ressources and energy to try to advance the field. A negative tweet is easy to write, but spending 5y to run a trial is another story https://twitter.com/Mohty_EBMT/status/1595293396297449472
We shouldn’t celebrate failure of a drug, celebrate learning instead because there’s always a path forward “I’ve missed more than 9000 shots in my career. I’ve lost almost 300 games…I’ve failed over and over and over again in my life. And that is why I succeed” – M Jordan #ASH22
Saad Kenderian (@kenderian_ss) of @MayoClinic discusses the current challenges and opportunities regarding CAR-T cell therapy and the tumor microenvironment at #SOHO22:
🎥: http://ow.ly/Kf0Q50LM7L3
#HemOnc #ImmunoOnc #CARTcell
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
